• xxx

QUEZADA, Sergio A Dr PH.D.

Group Leader, Immune Regulation and Tumour Immunotherapy Lab
CRUK Senior Cancer Research Fellow, UCL Cancer Institute.


Dr. Sergio Quezada is a Professorial Research Fellow and Group Leader at UCL Cancer Institute in London where he heads the Immune Regulation and Tumour Immunotherapy Laboratory. Prior to this, Dr. Quezada worked with Dr. James Allison at Memorial Sloan-Kettering Cancer Center studying the mechanisms governing anti-tumour T-cell immunity, and how these mechanisms can be manipulated for the generation of potent anti-tumour immune responses.


Dr. Quezada’s research interest at UCL remains focused in the study of the mechanism of action of anti-CTLA-4, anti-PD-1 and other immune-modulatory antibodies targeting co-inhibitory and co-stimulatory pathways (including ICOS, 4-1BB, OX-40) and used as novel anticancer therapies. His group has particular interest in the evolution of the immune response to cancer, the impact of immune-modulatory antibodies in the fate and function of tumour reactive T cells, and the role that the tumour microenvironment plays in the response and resistance to such therapies.


In the last years, through a number of clinical collaborations, his team gained significant expertise in the characterization and interrogation of the immune function within the microenvironment of different human cancers including melanoma, lung and kidney cancers. They expect their work to contribute to (1) the identification of relevant immune modulatory pathways controlling anti-tumour immunity in different cancers, (2) the understanding of the impact of conventional therapies in the expression of immune checkpoints, and (3) the design of novel rational combinations incorporating conventional-, targeted- and immune-based therapies.


Dr Quezada was the recipient of a Cancer Research UK Career Development Fellowship, Cancer Research Institute investigator Award and Dartmouth’s John W. Strohbern Medal for excellence in biomedical research. Most recently he was awarded with a Cancer Research UK Senior Cancer Research Fellowship.